Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis

Yueh Sheng Chen, Weng Tein Gi, Tin Yun Liao, Meng Tse Gabriel Lee, Si Huei Lee, Wan Ting Hsu, Shy Shin Chang, Chien Chang Lee

Research output: Contribution to journalReview article

13 Citations (Scopus)


Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.

Original languageEnglish
Pages (from-to)329-342
Number of pages14
JournalBiomarkers in Medicine
Issue number3
Publication statusPublished - Mar 1 2016
Externally publishedYes



  • Galectin-3
  • heart failure
  • prognostic marker

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this